- EYEN-6.4665%
(Adds analyst estimates in paragraph 6, background in paragraphs 9 and 10)
May 8 (Reuters) - The U.S. Food and Drug Administration (FDA) on Monday approved Eyenovia Inc's pupil-dilating spray for use with the company's proprietary drug delivery device during eye examinations.
The spray is indicated for mydriasis, or pupil dilation, for eye examinations carried out before cataract surgery or corrective prescriptions and can only be used in combination with the company's experimental drug delivery device, Optejet.
"We look forward to introducing Mydcombi to key offices beginning this summer while we bring our internal manufacturing capabilities on-line for 2024," Michael Rowe, chief executive officer of Eyenovia, said in a statement.
The FDA approval provides "critical validation" of Optejet, which Eyenovia is using to develop drugs for other indications, said Rowe, adding that the company was also exploring partnership options for the device.
Eyenovia is also testing Optejet in late-stage trials with its experimental drug to treat presbyopia, or gradual loss of near vision as part of aging.
Brokerage H.C. Wainwright analyst Matthew Caufield estimated Mydcombi to reach peak sales of $61.8 million globally by 2032.
In 2021, the FDA had reclassified Mydcombi as a drug-device combination product, given its dependence on Optejet for administration.
The U.S. health regulator had declined to approve the spray in its then-form as a standalone drug and requested additional device testing for Optejet. However, the agency had not requested any additional clinical work for Mydcombi.
The FDA approval is based on two late-stage studies that showed the spray improved the efficiency of office-based eye exams.
Optejet delivers the drug in microdoses and reduces chances of overdosing and exposure compared to conventional eyedroppers, the company said.
(Reporting by Aditya Samal and Mariam Sunny in Bengaluru; Editing by Subhranshu Sahu)
Recommended Stories
- Reuters
Pfizer CEO calls US drug price plan 'negotiation with a gun to your head'.
NEW YORK (Reuters) -Pfizer Inc Chief Executive Albert Bourla on Thursday called U.S. plans to negotiate drug prices for its Medicare health program "negotiation with a gun to your head" and said he expects drugmakers to sue in an attempt to halt the process. Bourla led Pfizer as the New York-based drugmaker raced alongside German partner BioNTech to develop a vaccine for COVID as much of the world locked down in 2020.
3h ago - Yahoo Finance
Why indie pharmacies, with the help of the likes of Mark Cuban, are on the rise.
Independent pharmacies and startups such as Cigna's Express Scripts and Mark Cuban's Cost Plus Drugs are partnering up to address a coverage gap for some Americans.
1d ago AdA.I. Brain's Precise Predictions Stun Wall Street.
Advanced A.I. "brain" consistently forecasts the stock market with up to 87.4% accuracy… 1-3 days in advance. Here's what it's seeing right now.
- Investopedia
Top Healthcare Stocks for May 2023.
Top healthcare stocks include Azenta Inc. for best value, ShockWave Medical for fastest growth, and Viking Therapeutics for most momentum.
7h ago - The Telegraph
Peloton recalls 2m bikes after seats falls off.
Peloton is recalling 2.2m exercise bikes after some users injured themselves when the seats broke off.
1h ago - Yahoo Finance
Novartis CEO criticizes US, EU efforts to curb drug company power.
Novartis CEO pushes back against government attempts to direct pharma R&D
1d ago AdMiami Beach: List Of Top Financial Advisor Firms Is Out.
Everyone knows they should consult a financial advisor for retirement planning, but how do you choose which one? This free tool makes it simple.
- Investor's Business Daily
Exact Sciences, Guardant Health Put Up Big Sales Beats As They Target The 'Most Preventable' Cancer.
Exact Sciences delivered a first-quarter report that "checked all the boxes," an analyst said as EXAS stock surged.
1d ago - Zacks
NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health.
NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.
3h ago - Benzinga
Elon Musk Says Neuralink Is The Only Way To Survive And Compete With AI.
Elon Musk, the genius behind SpaceX and Tesla Inc., has declared that humanity must embrace the merging of man and machine if we hope to survive in a world dominated by artificial intelligence (AI). In a 2018 appearance on the "Joe Rogan Experience," Musk teased his company Neuralink has something exciting in store for us. He believes his technology will allow humans to achieve a state of "symbiosis" with AI, where we’ll be able to effortlessly combine our brains with computers. Neuralink has be
1d ago AdHere Are 97 of the Coolest Gadgets for This 2023.
97 Insanely Cool Gadgets You'll Regret Not Getting Before They Sell Out
- Zacks
Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up.
Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development is on track.
1d ago - Benzinga
Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation.
Otsuka Pharmaceutical Co Ltd (OTC: OTSKF) (OTC: OTSKY) (Otsuka) and H. Lundbeck A/S have received FDA approval for Rexulti (brexpiprazole) for use in the treatment of agitation associated with dementia due to Alzheimer's disease. This approval makes Rexulti the first and only pharmacological treatment approved in the U.S. for agitation associated with dementia due to Alzheimer's disease. It is reported in approximately half of people with Alzheimer's dementia and is associated with earlier nursi
5h ago - Zacks
Thermo Fisher (TMO) Partners With Pfizer to Expand NGS Testing.
Thermo Fisher's (TMO) latest collaboration with Pfizer is set to enhance localized access to NGS-based testing capabilities for breast and lung cancer across international markets.
1d ago AdGet award-winning internet.
Google Fiber Webpass added thousands of new addresses in Miami in 2022 – and more to come.
- Benzinga
Good News For Toddlers With Peanut Allergy: DBVT Data Shows Promising Results for Peanut Allergy Patch.
DBV Technologies (NASDAQ: DBVT) (OTC: DBVTF) announced that its Phase 3 EPITOPE trial of epicutaneous immunotherapy (EPIT) with Viaskin Peanut in children 1 – 3 years was published in the New England Journal of Medicine. As stated in an accompanying editorial piece, these data are seen as "very good news" for toddlers with peanut allergy, as there are currently no approved treatment options for peanut-allergic children under the age of 4 years, the journal noted. After one year of treatment, Via
3h ago - AP Finance
Minnesota prepares for near-total ban on 'forever chemicals'.
Minnesota is on the verge of banning non-essential uses of "forever chemicals." Legislators, environmentalists and family members paid tribute Tuesday to Amara Strande. "Through her pain and exhaustion, Amara was willing to be a voice of those who have become the victims of illnesses that are linked to these forever chemicals," said her father, Michael Strande.
2d ago - Quartz
Italy's exports to China almost doubled in two months.
Italy’s exports to China reached a monthly record of €3 billion ($3.3 billion) in February, a 62% surge from the same period in 2022. That’s almost double their value of €1.7 billion last December, according to data that Banca d’Italia, the nation’s central bank, shared with Quartz. The unprecedented gain is entirely due to one product: ursodeoxycholic acid (UDCA), a generic drug used to treat gallstones and liver issues.
2d ago AdCut the cable. Switch to Verizon Home Internet..
Verizon Home Internet is built for next-gen gaming. Switch now and get Xbox Series S on us with a 5G Home Plus plan. Add'l terms apply.
- AP Finance
Mpox no longer a global emergency, WHO says.
The World Health Organization said Thursday that the global outbreak of mpox, which initially baffled experts when the smallpox-related disease spread to more than 100 countries last year, is no longer an international emergency, after a dramatic drop in cases in recent months. Last July, WHO Director-General Tedros Adhanom Ghebreyesus declared mpox, also known as monkeypox, to be an "extraordinary" situation that qualified as a global crisis. In doing so, he overruled WHO’s expert committee, which didn't recommend the emergency designation.
5h ago - SmartAsset
Ask an Advisor: Should I Pay off My Mortgage or Invest in CDs? I Refinanced My Mortgage at 2.375%, But I Can Get a CD at 4%. Plus, I Want to Retire in 7 Years..
I've been debating whether to pay off my mortgage. I've refinanced at 2.375% and can get a certificate of deposit (CD) for a year at 4%. I was adding to my mortgage payment by about $1,000 a month to pay … Continue reading → The post Ask an Advisor: Should I Pay off My Mortgage or Invest in CDs? I Refinanced My Mortgage at 2.375%, But I Can Get a CD at 4%. Plus, I Want to Retire in 7 Years. appeared first on SmartAsset Blog.
7h ago - CBS MoneyWatch
CNBC anchor who accused ex-CEO of sexual harassment to leave network.
A lawyer for Gamble said her client filed a sexual harassment complaint that led to the firing of NBCUniversal chief Jeff Shell.
1d ago AdLegendary Stock-Picker Names #1 Stock of 2023.
He called the bottom of the 2020 crash 24 hours before the greatest stock recovery in history. Here’s his #1 pick for 2023 (name and ticker).
- CBS MoneyWatch
Bud Light's parent company sees stock downgrade amid Mulvaney fallout.
Wall Street analysts placed a hold on Anheuser-Busch, citing last month's online promotion "crisis" with TikTok star.
2h ago - Zacks
KeyCorp (KEY) Hurt by Rising Expenses & Loan Concentration.
A lack of loan diversification and a steady rise in operating expenses are major near-term headwinds for KeyCorp (KEY).
6h ago - Benzinga
Warren Buffett Says, 'There's Nothing Better' Than This Strategy If You 'Do It At The Right Price.' Here Are 3 Companies Leading The Pack In This Area.
Companies can allocate their funds in various ways to create shareholder value. But in the eyes of legendary investor Warren Buffett, one method stands out above all others. "If you do it at the right price, there’s nothing better than buying in your own business," the Berkshire Hathaway CEO said during his company’s annual shareholders meeting in 2022. Buffett was referring to stock buybacks. Basically, a company can repurchase its own shares from the open market, effectively reducing the numbe
1d ago